相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)
M. Sznol et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.
R. C. Newton et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
K. Tamura et al.
ANNALS OF ONCOLOGY (2011)
被撤回的出版物: CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies (Retracted article. See vol. 134, pg. 658, 2019)
Holbrook E. Kohrt et al.
BLOOD (2011)
E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells
Chisako Yamauchi et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
Fubin Li et al.
SCIENCE (2011)
CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells
Tina Baessler et al.
BLOOD (2010)
CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells
Kerstin Juelke et al.
BLOOD (2010)
Human γδ T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement
Amudhan Maniar et al.
BLOOD (2010)
CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells
Hidehiko Narazaki et al.
BLOOD (2010)
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ
Juan Dubrot et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
4-1BB Ligand as an Effective Multifunctional Immunomodulator and Antigen Delivery Vehicle for the Development of Therapeutic Cancer Vaccines
Rajesh K. Sharma et al.
CANCER RESEARCH (2010)
Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo
Weijuan Gong et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2010)
Cellular Adaptive Immune System Plays a Crucial Role in Trastuzumab Clinical Efficacy
Filippo Bellati et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
CD137 Promotes Proliferation and Survival of Human B Cells
Xiaoyu Zhang et al.
JOURNAL OF IMMUNOLOGY (2010)
Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules
Kazuyoshi Takeda et al.
JOURNAL OF IMMUNOLOGY (2010)
Regulation of Granulocyte and Macrophage Populations of Murine Bone Marrow Cells by G-CSF and CD137 Protein
Dongsheng Jiang et al.
PLOS ONE (2010)
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
Roch Houot et al.
BLOOD (2009)
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab
Aruna Mani et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer
Philippe L. Bedard et al.
CURRENT CANCER DRUG TARGETS (2009)
Current perspective - Trastuzumab
Peter S. Hall et al.
EUROPEAN JOURNAL OF CANCER (2009)
In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb
Oihana Murillo et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Neil L. Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies
Tanios S. Bekaii-Saab et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Fc-dependent expression of CD137 on human NK cells: insights into agonistic effects of anti-CD137 monoclonal antibodies
Wei Lin et al.
BLOOD (2008)
Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates
Nikesh Kotecha et al.
CANCER CELL (2008)
Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells
Abbes Belkhiri et al.
CLINICAL CANCER RESEARCH (2008)
Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma
Oihana Murillo et al.
CLINICAL CANCER RESEARCH (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer
Nicolas Acquavella et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2
Stefania Varchetta et al.
CANCER RESEARCH (2007)
A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells:: Comparisons to a 4 h 51Cr-release assay
G. G. Kim et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
Immunostimulatory monoclonal antibodies for cancer therapy
Ignacio Melero et al.
NATURE REVIEWS CANCER (2007)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer
Philipp Kiewe et al.
CLINICAL CANCER RESEARCH (2006)
Apoptosis induction by trastuzumab:: Possible role of the core biopsy intervention
S Ménard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells
JA Bowles et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers
SK Mohsin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response
WL Gluck et al.
CLINICAL CANCER RESEARCH (2004)
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
R Gennari et al.
CLINICAL CANCER RESEARCH (2004)
Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity
RA Wilcox et al.
JOURNAL OF IMMUNOLOGY (2002)
Cutting edge: expression of functional CD137 receptor by dendritic cells
RA Wilcox et al.
JOURNAL OF IMMUNOLOGY (2002)
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
SM Ansell et al.
BLOOD (2002)
The biology of human natural killer-cell subsets
MA Cooper et al.
TRENDS IN IMMUNOLOGY (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
